The intriguing case for GIPR antagonism, supported by genetics, pharmacology and Maritide is presented by Rosenkilde, George, Veniant and Holst #weightloss ##obesity https://t.co/BRYzffz2gU @Diabetes_ADA@AmDiabetesAssn
As we head to the 2025 @AmDiabetesAssn GIP biology will be part of the conversation. Here Samms and Sloop summarize the compelling scientific story of Tirzepatide and the case for GIPR co-agonism #Diabetes#Weightloss#obesity https://t.co/M5UMnAsl0w
@PaulTitchenell@kaheaisu@jclinicalinvest Really nice work Paul. I really like the use of physiological feeding as an intervention. Have you thought about how glucagon touches this pathway and the impact on glycogen?
https://t.co/syG4uT7TLf
Your fat cells listen and talk. Here, you can read about how surrounding stromal cells in adipose tissue are also getting in on the conversation. New review from @jessicacannavi1@DukeMPI@dukeendocrinol1
“Signs of glucagon resistance after a two-week hypercaloric diet intervention”
#T2D#Pathophysiology
Huge amount of experimental work, facinating results and data-driven conclusions beautifully presented by @MalteSuppli in Hamburg Hall #EASD2023🎯🤩👏🏼
https://t.co/1QN7kmWvTt